Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

News

iCMLf Forum 2016: View webstreams on 'Managing the high risk CML patient'

iCMLf Forum 2016 Podium

February 2017 - Webstreams of the presentations from the iCMLf Forum for Physicians from Emerging Regions 2016 are now available to view. This year's Forum focused on 'Managing the high risk CML patient'. Presenters give the local emerging regions perspectives on each topic followed iCMLf experts and a discussion with the audience.

Topics include:

  1. Meeting the new challenges in CML therapy 
    Professor Brian Druker (USA) 
  2. Frontline therapy challenges 
    Professor Tapan Saikia (India) and Professor Andreas Hochhaus (Germany)
  3. Comorbidities when managing CML
    Dr Anthony Oyekunle (Botswana) and Dr Delphine Réa (France)

Click on the presentations below to view the webstreams and see the slides.
(We are very grateful for the support of Brandcast media to produce these web streams)  

 

 

iCMLf Forum 2016 Brian Druker

Prof. Brian Druker
Portland, USA

Keynote: Meeting the new challenges in CML therapy 

Topics and questions raised include; current state of CML, challenges for patients on long-term therapy, How can we move from control to cure?, Do we need to eradicate stem cells?, Can the immune system control CML?, challenges for clinical trials.

 

 

 

 

 

iCMLf Forum 2016 Tapan Saikia

Prof. Tapan Saikia
Mumbai, India

Frontline therapy challenges:
High-risk chronic myeloid leukemia: An emerging country's perspective

Topics include; high-risk CML cases, current treatment for high-risk CML-CP: Indian scenarios, availability of TKI's for CML in India, possibilities of using TKI's in high risk CML in India, challenges in managing high-risk patients. 

 

 

 

 

iCMLf Forum 2016 Andreas Hochhaus

Prof. Andreas Hochhaus
Jena, Germany

Frontline therapy challenges

Topics include; challenge 1: initial therapy, challenge 2: additional therapy to avoid adverse events, challenge 3: prognostic score, challenge 4: unfavourable bone marrow data, challenge 5: choice of initial therapy, case studies on tests to start TKI and follow-up. 

 

 

 

iCMLf Forum 2016 Pat Garcia Gonzalez

 Pat Garcia-Gonzalez

Seattle, USA

Q&A Session 1: Frontline therapy challenges  

Moderated by Pat Garcia-Gonzalez, CEO The MAX Foundation                                       

 

 

 

 

iCMLf Forum 2016 Anthony OyekunleDr Anthony Oyekunle
Gaborone, Botswana

Comorbities when managing CML with TKI's:
An emerging country's perspective 

Topics include; managing CML with TKI's, the case for comorbities, What is the impact of comorbidities on overall survival in CML? key outcomes from various studies, conclusion.

 

 

 

 

 

iCMLf Forum 2016 Delphine Rea.pngDr Delphine Réa
Paris, France

Managing CML patients with comorbidities

Topics include; prevalence of comorbidities among CML patients, impact of comorbidities on 1st line imatinib efficacy in CP-CML, impact of comorbidities on overall survival after 1st line imatinib treatment in CP-CML, results from the DASISION and ENESTnd trials, discussion on comorbidities may guide TKI choice in the first line seeting, conclusion. 

 

 

 

 

 

iCMLf Forum 2016 Pat Garcia Gonzalez
Pat Garcia-Gonzalez
Seattle, USA

Q&A Session 2: Comorbidities when managing CML 

 Moderated by Pat Garcia-Gonzalez, CEO The MAX Foundation